Regulatory Alert: CDSCO Suspends HCG Bengaluru Ethics Committee Following Compliance Failures

In a significant regulatory move, the Central Drugs Standard Control Organization (CDSCO) has suspended the Registration of the Ethics Committee (EC) of the HCG Bangalore Institute of Oncology for a period of 24 months, effective from June 12, 2026.

This action follows a risk-based inspection conducted in July 2025 by a joint team of central and state regulators, which uncovered multiple critical lapses in adherence to the New Drugs and Clinical Trials Rules (NDCTR), 2019.

Key Findings of the Regulatory Investigation

The CDSCO’s suspension order highlights several serious violations that directly impacted participant safety and regulatory integrity:

  • Failure to Report Serious Adverse Events (SAEs): The committee failed to report nine SAEs to the Central Licensing Authority (CLA), including three cases involving deaths. Furthermore, many reported events were submitted well beyond the mandated 30-day timeline.
  • Conflict of Interest: A significant breach of protocol occurred when a clinical expert served on the Ethics Committee while simultaneously acting as a Principal Investigator (PI) for a study. The individual allegedly signed a declaration of “no conflict of interest” despite the dual roles.
  • Participant Safety & Management: The regulator flagged instances where trial participants were not provided with adequate medical management. Notably, in one case involving a subject who later died, the committee failed to ensure proper follow-up and subsequently did not accurately reflect the event’s causality in reports submitted to the CLA.
  • Administrative & Protocol Lapses: The investigation cited incomplete documentation, including failures to maintain the required quorum for meetings and a lack of transparency regarding protocol deviations.

What This Means for Ongoing Research

While the 24-month suspension bars the HCG Bangalore Institute of Oncology’s Ethics Committee from overseeing or initiating any new clinical trials or BA-BE (Bioavailability/Bioequivalence) studies, the regulator has mandated that the committee must continue to monitor existing, ongoing trials.

The CDSCO has instructed the institution to:

  1. Submit a comprehensive Corrective and Preventive Action (CAPA) plan to address the identified failures.
  2. Provide regular monthly status reports to the CLA and the CDSCO Zonal Office in Bengaluru to ensure the continued safety and well-being of participants currently enrolled in active trials.

The Bigger Picture

This action serves as a stern reminder of the non-negotiable role ethics committees play in the clinical research ecosystem. Their primary mandate is the protection of human participants. When administrative oversight, transparency, and conflict-of-interest protocols are compromised, it not only delays research but fundamentally undermines public trust in clinical trials.

The hospital chain has issued a statement noting that it is examining the order and exploring its legal options, emphasizing that the suspension is limited to this specific ethics committee unit and does not impact their broader financial operations.

Regulatory Update /Notice :

Leave a Reply

Your email address will not be published. Required fields are marked *